1. Home
  2. IVA vs EMBC Comparison

IVA vs EMBC Comparison

Compare IVA & EMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IVA
  • EMBC
  • Stock Information
  • Founded
  • IVA 2011
  • EMBC 1924
  • Country
  • IVA France
  • EMBC United States
  • Employees
  • IVA N/A
  • EMBC N/A
  • Industry
  • IVA Biotechnology: Pharmaceutical Preparations
  • EMBC Medical/Dental Instruments
  • Sector
  • IVA Health Care
  • EMBC Health Care
  • Exchange
  • IVA Nasdaq
  • EMBC Nasdaq
  • Market Cap
  • IVA 769.0M
  • EMBC 788.4M
  • IPO Year
  • IVA 2020
  • EMBC N/A
  • Fundamental
  • Price
  • IVA $5.61
  • EMBC $15.01
  • Analyst Decision
  • IVA Strong Buy
  • EMBC Buy
  • Analyst Count
  • IVA 6
  • EMBC 2
  • Target Price
  • IVA $15.33
  • EMBC $18.50
  • AVG Volume (30 Days)
  • IVA 74.4K
  • EMBC 485.7K
  • Earning Date
  • IVA 09-26-2025
  • EMBC 08-08-2025
  • Dividend Yield
  • IVA N/A
  • EMBC 3.98%
  • EPS Growth
  • IVA N/A
  • EMBC 18.26
  • EPS
  • IVA N/A
  • EMBC 1.42
  • Revenue
  • IVA $14,591,573.00
  • EMBC $1,102,500,000.00
  • Revenue This Year
  • IVA $80.35
  • EMBC N/A
  • Revenue Next Year
  • IVA N/A
  • EMBC N/A
  • P/E Ratio
  • IVA N/A
  • EMBC $10.60
  • Revenue Growth
  • IVA N/A
  • EMBC N/A
  • 52 Week Low
  • IVA $1.53
  • EMBC $9.20
  • 52 Week High
  • IVA $6.50
  • EMBC $21.48
  • Technical
  • Relative Strength Index (RSI)
  • IVA 60.84
  • EMBC 64.45
  • Support Level
  • IVA $5.21
  • EMBC $14.51
  • Resistance Level
  • IVA $5.78
  • EMBC $15.44
  • Average True Range (ATR)
  • IVA 0.38
  • EMBC 0.51
  • MACD
  • IVA -0.02
  • EMBC -0.05
  • Stochastic Oscillator
  • IVA 54.82
  • EMBC 72.99

About IVA Inventiva S.A. American Depository Shares

Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.

About EMBC Embecta Corp.

Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.

Share on Social Networks: